Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis

Bissett, Sara L.; Godi, Anna; Jit, Mark; Beddows, Simon

doi:10.1016/j.vaccine.2017.06.028

Cited by 25 publications

(20 citation statements)

References 43 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neutralizing antibodies against vaccine genotypes can be detected in the serum and genital secretions of vaccinees and passive transfer of neutralizing antibodies can protect animals against papillomavirus challenge, leading to the reasonable assumption that type-specific protection is mediated by neutralizing antibodies [3]. The degree of cross-protection afforded by the HPV vaccines appears to be consistent with the detection of cross-neutralizing antibodies [6] suggesting that such antibodies may be effectors or their detection may be useful as a correlate or surrogate of vaccine-induced cross-protection.…”

Section: Introductionmentioning

confidence: 94%

Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine

Godi

Panwar

Haque

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

Bivalent (Cervarix®) and quadrivalent (Gardasil®) Human Papillomavirus (HPV) vaccines demonstrate remarkable efficacy against the targeted genotypes, HPV16 and HPV18, but also a degree of cross-protection against non-vaccine incorporated genotypes, HPV31 and HPV45. These outcomes seem to be supported by observations that the HPV vaccines induce high titer neutralizing antibodies against vaccine types and lower responses against non-vaccine types. Few data are available on the robustness of the immune response against non-vaccine types. We examined the durability of vaccine and non-vaccine antibody responses in a follow up of a head-tohead study of 12-15 year old girls initially randomized to receive three doses of Cervarix® or Gardasil® vaccine. Neutralizing antibodies against both vaccine and non-vaccine types remained detectable up to 7 years following initial vaccination and a mixed effects model was used to predict the decline in antibody titers over a 15 year period. The decline in vaccine and non-vaccine type neutralizing antibody titers over the study period was estimated to be 30% every 5-7 years, with Cervarix® antibody titers expected to remain 3-4 fold higher than Gardasil® antibody titers over the long term. The antibody decline rates in those with an initial response to non-vaccine types were similar to that of vaccine types and are predicted to remain detectable for many years. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention. Original trial: ClinicalTrials.gov NCT00956553

show abstract

Section: Introductionmentioning

confidence: 94%

Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine

Godi

Panwar

Haque

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The 9-valent may be cost-effective depending on the price of the vaccine and the setting 131 . Cross-protection against types 31, 33 and 45 has been seen for the 2-valent vaccine, more limited against type 31 for the 4-valent vaccine and it seems that high vaccination coverage is needed for cross-protection to appear 133,135 .…”

Section: Hpv Vaccinationmentioning

confidence: 99%

Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia

Carlander

Wagner

Beirs

et al. 2018

Aids

View full text Add to dashboard Cite

show abstract

“…In addition, available vaccines have shown cross-protection against non-vaccine HPV strands. [91,92]. In Sweden, HPV vaccination for girls has been included in the national vaccination program since 2010.…”

Section: Hpv Vaccinesmentioning

confidence: 99%

Expression of Psoriasin in Human Papillomavirus–Induced Cervical High-Grade Squamous Intraepithelial Lesions

Alvendal

Kamolvit

Wagner

et al. 2019

J Low Genit Tract Dis

View full text Add to dashboard Cite

Background: Infections of the female genital tract are common and have severe impact on the quality of life and sexual health of affected women. The innate immune system is crucial and is involved in the defense of infections. Understanding innate immunity of the vaginal and cervical mucosa is important to enable development of future preventive and therapeutic strategies for genital infections. Objective: The aim of this thesis was to investigate innate immune factors in women with recurrent candida vulvovaginitis (RVVC) and high grade squamous intraepithelial lesions (HSIL) of the cervix, induced by human papilloma virus (HPV). This in order to contribute to the understanding of the innate immune response in these two common infections of the lower female genital tract. Material and Methods: Clinical examinations, measurements of intravaginal nitric oxide (NO) levels and vaginal biopsies were performed in 28 patients with RVVC and 31 healthy controls. Cervical biopsies and vaginal lavage were collected from 19 patients with HPV induced HSIL and 14 controls. Immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), western blot and reverse transcriptase real time polymerase chain reaction (PCR)) were used to identify and quantify inducible nitric oxide synthase (iNOS), antimicrobial proteins, cytokines and encoding genes. Adhesion and binding assays were performed to evaluate the adhesive capacity of candida and to demonstrate the binding between candida and the antimicrobial protein psoriasin. Transmission electron microscopy was conducted to measure the cell wall thickness in C. albicans affected by psoriasin. To evaluate a new treatment strategy for RVVC, the effect of chlorhexidine digluconate and fluconazole on C. albicans eradication and biofilm was investigated in RVVC and commensal strains, using the crystal violet method and viable count. Results: NO levels were significantly higher in patients during acute infection compared to controls. Levels decreased after fluconazole treatment but remained higher than in controls. Furthermore, increased expression of iNOS was observed in the epithelial basal layer in patients both before and after treatment. There were positive correlations between NO levels, clinical symptoms and examination scores. Findings indicated that C. albicans induces production of psoriasin during mucosal candida infection. Psoriasin was shown to interact with β-glucan in the candida cell wall and inhibit candida adhesion to surfaces. In HPV induced HSIL, psoriasin expression and protein levels increased significantly after surgical treatment and reached similar levels as in controls. The mRNA expression of the proinflammatory cytokine IL-8 was higher before treatment and restored to the same levels as in controls six months after lesions were excised. Chlorhexidine digluconate prevented new biofilm formation and reduced already established C. albicans biofilm. Moreover, the number of candida cells in both planktonic state and within the biofilm were significantly decreased....

show abstract

Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis

Abstract: These data improve our understanding of vaccine-induced functional antibody specificity against non-vaccine incorporated genotypes and may help to parameterize vaccine-impact models and improve patient management in a post-vaccine setting.

Cited by 25 publications

References 43 publications

Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine

Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine

Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia

Expression of Psoriasin in Human Papillomavirus–Induced Cervical High-Grade Squamous Intraepithelial Lesions

Contact Info

Product

Resources

About